Data from 30 trials (n = 4102 patients) were included and, after a meta-analysis, it was noted that at one year, those recipients treated with tacrolimus had more insulin-requiring DM (risk ratio 1.86; CI 1.11–3.09)36. Here, INS is linked to diabetes mellitus.